Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLYM NASDAQ:IRON NASDAQ:MOR NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$12.90$11.22$1.21▼$13.69$738.69M0.071.56 million shs1.18 million shsIRONDisc Medicine$76.26$69.36$40.00▼$99.50$2.91B0.97765,044 shs985,673 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ASLSSELLAS Life Sciences Group$14.98$8.11$1.39▼$15.88$2.95B2.4210.33 million shs17.22 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio0.00%-1.38%+18.24%+96.65%+923.81%IRONDisc Medicine0.00%+1.98%+7.24%+17.00%+43.43%MORMorphoSys0.00%0.00%0.00%0.00%0.00%SLSSELLAS Life Sciences Group0.00%+20.90%+65.71%+262.71%+606.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$12.90$11.22$1.21▼$13.69$738.69M0.071.56 million shs1.18 million shsIRONDisc Medicine$76.26$69.36$40.00▼$99.50$2.91B0.97765,044 shs985,673 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ASLSSELLAS Life Sciences Group$14.98$8.11$1.39▼$15.88$2.95B2.4210.33 million shs17.22 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio0.00%-1.38%+18.24%+96.65%+923.81%IRONDisc Medicine0.00%+1.98%+7.24%+17.00%+43.43%MORMorphoSys0.00%0.00%0.00%0.00%0.00%SLSSELLAS Life Sciences Group0.00%+20.90%+65.71%+262.71%+606.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLYMClimb Bio 3.07Buy$21.7368.43% UpsideIRONDisc Medicine 2.73Moderate Buy$104.4436.96% UpsideMORMorphoSys 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 2.00Hold$10.00-33.24% DownsideCurrent Analyst Ratings BreakdownLatest CLYM, SLS, IRON, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/15/2026IRONDisc Medicine Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$80.00 ➝ $85.006/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/10/2026IRONDisc Medicine WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$88.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.005/14/2026IRONDisc Medicine Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$75.00 ➝ $80.005/12/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/8/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $17.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/AIRONDisc MedicineN/AN/AN/AN/A$19.52 per shareN/AMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)IRONDisc Medicine-$212.18M-$6.62N/AN/AN/AN/A-36.94%-33.88%8/6/2026 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ASLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest CLYM, SLS, IRON, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/A5/5/2026Q1 2026IRONDisc Medicine-$1.6227-$1.65-$0.0273-$1.65$0.44 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLYMClimb BioN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLYMClimb BioN/A27.8627.86IRONDisc Medicine0.0424.0024.00MORMorphoSys4.981.381.38SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLYMClimb Bio69.76%IRONDisc Medicine83.70%MORMorphoSys18.38%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipCLYMClimb Bio2.60%IRONDisc Medicine3.76%MORMorphoSys0.05%SLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLYMClimb Bio957.26 million55.77 millionN/AIRONDisc Medicine3038.16 million36.73 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableCLYM, SLS, IRON, and MOR HeadlinesRecent News About These CompaniesMost and least shorted mid- to mega-cap healthcare stocks at the end of JuneJuly 1, 2026 | seekingalpha.comSELLAS Life Sciences Group (SLS) Stock Looks Above Fair Value Before Key Trial DataJuly 1, 2026 | finance.yahoo.comSELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 52-Week High - Should You Buy?July 1, 2026 | americanbankingnews.comDoes SELLAS (SLS) Executive Severance Reset Hint at M&A Readiness or Standalone Ambition?June 30, 2026 | uk.finance.yahoo.comWhy Sellas Remains A Strong Sell After Doubling In PriceJune 30, 2026 | seekingalpha.comSELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?June 30, 2026 | benzinga.comSellas Life (SLS) Climbs to Record High on Acquisition BuzzJune 30, 2026 | finance.yahoo.comSellas Life Sciences shares break out to new 52-week high: What's driving the momentum?June 29, 2026 | msn.comIs SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?June 29, 2026 | insidermonkey.comWhy did SLS, MRNA, ABCL stocks surge to 52-week highs last week?June 28, 2026 | msn.comSellas Life Sciences: The AML Platform Is More Interesting Than The Binary EventJune 27, 2026 | seekingalpha.comSELLAS Life Sciences jumps as traders focus on imminent REGAL trial catalyst and stronger cash positionJune 26, 2026 | quiverquant.comQSELLAS stock hits new highs: What's happening today?June 26, 2026 | msn.comWhat's driving SLS stock higher today and what comes next?June 26, 2026 | invezz.comISLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout ChatterJune 26, 2026 | finance.yahoo.comSellas (SLS) Extends Rally, New Filing Hints at Company TakeoverJune 26, 2026 | insidermonkey.comSLS stock up 13% as executive severance updates reignite buyout speculationJune 25, 2026 | msn.comSLS stock slips overnight: Shareholders approve 20M new shares, CEO awarded 1M RSUsJune 22, 2026 | msn.comWhat Does Strong Shareholder Support Mean for SELLAS Life Sciences Group (NASDAQ:SLS)?June 19, 2026 | kalkinemedia.comKSELLAS Stockholders Approve Governance and Equity Plan ChangesJune 18, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesA Market Rotation Toward Quality Will Benefit These 3 ETFsBy Nathan Reiff | June 8, 2026Energy Fuels Just Made a Bold Bet on Rare Earth MagnetsBy Jeffrey Neal Johnson | June 25, 20263 Rate-Ready Stocks for the New Fed Chair’s First Big TestBy Chris Markoch | June 16, 20262 Space and Defense Stocks Turning Backlogs Into Revenue GrowthBy Nathan Reiff | June 25, 2026Why Wall Street Still Sees Massive Upside for AeroVironment StockBy Thomas Hughes | June 30, 2026CLYM, SLS, IRON, and MOR Company DescriptionsClimb Bio NASDAQ:CLYM$12.90 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$12.90 0.00 (0.00%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Disc Medicine NASDAQ:IRON$76.26 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$76.33 +0.07 (+0.10%) As of 07/2/2026 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/2/2026MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.SELLAS Life Sciences Group NASDAQ:SLS$14.98 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$14.81 -0.17 (-1.13%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
